Evidence map›Paper›PMID 33781762›Full record

ArticleContraception2021

Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic.

Erica Chong, Tara Shochet, Elizabeth Raymond, Ingrida Platais, Holly A Anger, Shandhini Raidoo, Reni Soon, Melissa S Grant, Susan Haskell, Kristina Tocce and 8 more

Abstract read
In one paragraph

Article in Contraception, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Telemedicine for First-Trimester Medical Abortion in Canada: Results of a 2019 Survey.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Erica ChongGynuity Health Projects, New York, NY, USA; Present address: Reproductive Health Education in Family Medicine, 3544 Jerome Avenue, Bronx, NY 10467.. Electronic address: erchong@montefiore.org.
Tara ShochetGynuity Health Projects, New York, NY, USA.
Elizabeth RaymondGynuity Health Projects, New York, NY, USA.
Ingrida PlataisGynuity Health Projects, New York, NY, USA.
Holly A AngerGynuity Health Projects, New York, NY, USA.
Shandhini RaidooDepartment of Obstetrics, Gynecology, and Women's Health, University of Hawaii John A. Burns School of Medicine, Honolulu, HI, USA.
Reni SoonDepartment of Obstetrics, Gynecology, and Women's Health, University of Hawaii John A. Burns School of Medicine, Honolulu, HI, USA.
Melissa S Grantcarafem, 1001 Connecticut Avenue NW, Washington, DC, USA.
Susan Haskellcarafem, 1001 Connecticut Avenue NW, Washington, DC, USA.
Kristina ToccePlanned Parenthood of the Rocky Mountains, Denver, CO, USA.
Maureen K BaldwinOregon Health and Science University, Portland, OR, USA.
Christy M BoraasPlanned Parenthood MN-ND-SD, St. Paul, MN, USA.
Paula H BednarekPlanned Parenthood Columbia Willamette, Portland, OR, USA.
Joey BanksPlanned Parenthood of Montana, Missoula, MT, USA.
Leah CoplonMaine Family Planning, Augusta, ME, USA.
Francine ThompsonEmma Goldman Clinic, Iowa City, IA, USA.
Esther PriegueChoices Women's Medical Center, New York, NY, USA.
Beverly WinikoffGynuity Health Projects, New York, NY, USA.

Funding

OHSU Women's Reproductive Health Research K12 ProgramK12HD085809 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Aaron B Caughey · 2015 to 2026
$4.0M
NICHD NIH HHS K12 HD085809
6 · The paper itself

Abstract

objectiveTo present updated evidence on the safety, efficacy and acceptability of a direct-to-patient telemedicine abortion service and describe how the service functioned during the COVID-19 pandemic. STUDY

designWe offered the study at 10 sites that provided the service in 13 states and Washington DC. Interested individuals obtained any needed preabortion tests locally and had a videoconference with a study clinician. Sites sent study packages containing mifepristone and misoprostol by mail and had remote follow-up consultations within one month by telephone (or by online survey, if the participant could not be reached) to evaluate abortion completeness. The analysis was descriptive.

resultsWe mailed 1390 packages between May 2016 and September 2020. Of the 83% (1157/1390) of abortions for which we obtained outcome information, 95% (1103/1157) were completed without a procedure. Participants made 70 unplanned visits to emergency rooms or urgent care centers for reasons related to the abortion (6%), and 10 serious adverse events occurred, including 5 transfusions (0.4%). Enrollment increased substantially with the onset of COVID-19. Although a screening ultrasound was required, sites determined in 52% (346/669) of abortions that occurred during COVID that those participants should not get the test to protect their health. Use of urine pregnancy test to confirm abortion completion increased from 67% (144/214) in the 6 months prior to COVID to 90% (602/669) in the 6 months during COVID. Nearly all satisfaction questionnaires (99%, 1013/1022) recorded that participants were satisfied with the service.

conclusionsThis direct-to-patient telemedicine service was safe, effective, and acceptable, and supports the claim that there is no medical reason for mifepristone to be dispensed in clinics as required by the Food and Drug Administration. In some cases, participants did not need to visit any facilities to obtain the service, which was critical to protecting patient safety during the COVID-19 pandemic. IMPLICATIONS: Medical abortion using telemedicine and mail is effective and can be safely provided without a pretreatment ultrasound. This method of service delivery has the potential to greatly improve access to abortion care in the United States.

Indexed as

COVID-19Postal ServiceAbortifacient Agents, NonsteroidalAbortifacient Agents, SteroidalAbortion, InducedAdolescentAdultFemaleHumansMiddle AgedMifepristoneMisoprostolPregnancySARS-CoV-2TelemedicineUnited StatesAbortifacient Agents, NonsteroidalAbortifacient Agents, SteroidalMifepristoneMisoprostolCOVID-19MailMedical abortionTelemedicineUnited States

Identifiers

PMID33781762
PMCPMC9748604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.